Related references
Note: Only part of the references are listed.Temporal Trends in Presentation and Survival for HIV-Associated Lymphoma in the Antiretroviral Therapy Era
Satish Gopal et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
Pooled analysis of AIDS malignancy consortium trials evaluating rituximab plus CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin lymphoma
Stefan K. Barta et al.
CANCER (2012)
HIV Status Does Not Influence Outcome in Patients With Classical Hodgkin Lymphoma Treated With Chemotherapy Using Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine in the Highly Active Antiretroviral Therapy Era
Silvia Montoto et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Stage-Adapted Treatment of HIV-Associated Hodgkin Lymphoma: Results of a Prospective Multicenter Study
Marcus Hentrich et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma
Joseph A. Sparano et al.
BLOOD (2010)
The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma
Kieron Dunleavy et al.
BLOOD (2010)
Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy
Ian Weller et al.
AIDS (2009)
Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma
Kieron Dunleavy et al.
BLOOD (2009)
Stromal Gene Signatures in Large-B-Cell Lymphomas
G. Lenz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
AIDS-related lymphomas: from pathogenesis to pathology
A Carbone et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology
RF Little et al.
BLOOD (2003)
Share Paper
